Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aileron Therapeutics Inc

ALRN
Current price
2.75 USD 0 USD (0.00%)
Last closed 2.77 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 64 844 400 USD
Yield for 12 month +49.46 %
1Y
3Y
5Y
10Y
15Y
ALRN
21.11.2021 - 28.11.2021

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas. Address: 285 Summer Street, Boston, MA, United States, 02210

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

+134 000 USD

Last Quarter

Current Year

-119 000 USD

Last Year

-169 000 USD

Current Quarter

+82 000 USD

Last Quarter

Key Figures ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -18 429 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -19.94 %
PEG Ratio
Return On Equity TTM -34.21 %
Wall Street Target Price 13 USD
Revenue TTM
Book Value 2.66 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -17 008 000 USD
Earnings per share -3.23 USD
Diluted Eps TTM -3.23 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALRN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 11.11.2022
Dividend Date

Stock Valuation ALRN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.6953
Price Book MRQ 2.6788

Financials ALRN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALRN

For 52 weeks

1.01 USD 7.42 USD
50 Day MA 3.26 USD
Shares Short Prior Month 140 356
200 Day MA 3.57 USD
Short Ratio 3.19
Shares Short 272 876
Short Percent 1.26 %

Dynamics of changes in the value of assets

G

GBRGW

0.13 USD Goldenbridge Acquisition Limited -0.01 (-8.77%)
Detailed analytics
A

ARA

0.50 AUD Ariadne Australia Ltd 0 (0%)
Detailed analytics
B

BIOQ

72.50 USD Bioqual Inc 0 (0%)
Detailed analytics
K

KGF

277.10 GBX Kingfisher PLC +0.02 (+0.43%)
Detailed analytics
P

PKART

93.70 TRY Plastikkart Akilli Kart Iletisim Sistemleri Sanayi ve Ticaret AS +0.08 (+2.97%)
Detailed analytics